Search - tctmd.com

Displaying 241 - 260 of 388

Sort: Relevancy | Date

News Daily News

Alirocumab ‘Modestly’ Cost-effective at Lower List Price: ODYSSEY OUTCOMES

Michael O'Riordan

May 04, 2020

News Features

COVID-19 Lockdown Inactivity May Spell Trouble for CVD Prevention

Michael O'Riordan

April 24, 2020

News Conference News ACC 2020

Icosapent Ethyl’s CV Benefit Closely Tied to Serum EPA Levels: REDUCE-IT

Todd Neale

April 02, 2020

News Conference News ACC 2020

Pooled Inclisiran Data: Safe LDL-Lowering, Plus Hints of Fewer CVD Events

Michael O'Riordan

April 02, 2020

News Daily News

Ideal CV Health Over the Long Term Linked With Better Survival, Less Disease

Michael O'Riordan

March 13, 2020

News Daily News

LEADER Analysis Reassures on Liraglutide in Diabetic Patients With Heart Failure

Shelley Wood

March 10, 2020

News Daily News

Type 2 MI Linked to More CV Deaths, Even in Younger Patients

Shelley Wood

March 04, 2020

News Daily News

Snapshot of Revascularization Outcomes Offers Some Reassurances, Some Surprises

Shelley Wood

February 14, 2020

News Daily News

Trials of New Cancer Drugs Failing to Address Potential CV Risks

Todd Neale

February 10, 2020

News Daily News

Patient-Level Data Strengthen Rosiglitazone-CV Link: Meta-analysis

Caitlin E. Cox

February 07, 2020

News Daily News

Pot Talk: Review Urges Cardiologists to Discuss Marijuana Use

L.A. McKeown

January 21, 2020

News Daily News

Injectable GLP-1 Agonist Semaglutide Gets CVD Event Reduction Indication

Michael O'Riordan

January 17, 2020

News Daily News

Hypertension Starts Years Earlier in Women Than Men, Serial BP Shows

L.A. McKeown

January 17, 2020

News Daily News

Year in Review: New Guidelines, Inclisiran, Dapagliflozin Impact CVD Prevention in 2019

Yael L. Maxwell

December 20, 2019

News Daily News

Aspirin Not Protective Against CVD in Black Patients

Caitlin E. Cox

December 18, 2019

News Daily News

FDA Approves Icosapent Ethyl for Reducing CVD Events

Michael O'Riordan

December 13, 2019

News Daily News

Non-HDL Cholesterol Strongly Tied to Lifetime CVD Risk

Michael O'Riordan

December 03, 2019

News Daily News

Grief and CVD: Simple Regimen May Lower Risk

L.A. McKeown

November 19, 2019

News Daily News

FDA Advisors Recommend CVD Event Reduction Claim for Icosapent Ethyl

Michael O'Riordan

November 14, 2019

News Daily News

Nighttime Hypertension Drug Dosing May Reduce Risk of CVD

L.A. McKeown

October 23, 2019

Advertisement

Alirocumab ‘Modestly’ Cost-effective at Lower List Price: ODYSSEY OUTCOMES

COVID-19 Lockdown Inactivity May Spell Trouble for CVD Prevention

Icosapent Ethyl’s CV Benefit Closely Tied to Serum EPA Levels: REDUCE-IT

Pooled Inclisiran Data: Safe LDL-Lowering, Plus Hints of Fewer CVD Events

Ideal CV Health Over the Long Term Linked With Better Survival, Less Disease

LEADER Analysis Reassures on Liraglutide in Diabetic Patients With Heart Failure

Type 2 MI Linked to More CV Deaths, Even in Younger Patients

Snapshot of Revascularization Outcomes Offers Some Reassurances, Some Surprises

Trials of New Cancer Drugs Failing to Address Potential CV Risks

Patient-Level Data Strengthen Rosiglitazone-CV Link: Meta-analysis

Pot Talk: Review Urges Cardiologists to Discuss Marijuana Use

Injectable GLP-1 Agonist Semaglutide Gets CVD Event Reduction Indication

Hypertension Starts Years Earlier in Women Than Men, Serial BP Shows

Year in Review: New Guidelines, Inclisiran, Dapagliflozin Impact CVD Prevention in 2019

Aspirin Not Protective Against CVD in Black Patients

FDA Approves Icosapent Ethyl for Reducing CVD Events

Non-HDL Cholesterol Strongly Tied to Lifetime CVD Risk

Grief and CVD: Simple Regimen May Lower Risk

FDA Advisors Recommend CVD Event Reduction Claim for Icosapent Ethyl

Nighttime Hypertension Drug Dosing May Reduce Risk of CVD

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content